A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Byron Dorgan Biography and Net Worth

Director of Codexis

Byron Dorgan brings experience in policy making, government affairs and financial management having represented North Dakota in the U.S. Senate from 1992 to 2011 and in the House of Representatives from 1981 to 1992. He served as assistant Democratic floor leader, chairman of the Democratic Policy Committee and chairman of the Committee on Indian Affairs and also was the senior senator on the Appropriations, Energy and Commerce committees.

Prior to being elected to Congress, Dorgan served as North Dakota’s state tax commissioner from 1969 until 1980. The author of four books on governmental policy, Dorgan earned a bachelor’s from the University of North Dakota and an MBA from the University of Denver.

What is Byron L. Dorgan's net worth?: The estimated net worth of Byron L. Dorgan is at least $547,494.63 as of November 15th, 2023. Mr. Dorgan owns 193,461 shares of Codexis stock worth more than $547,495 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Dorgan may own. Learn More about Byron L. Dorgan's net worth.
How do I contact Byron L. Dorgan?: The corporate mailing address for Mr. Dorgan and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Byron L. Dorgan's contact information.
Has Byron L. Dorgan been buying or selling shares of Codexis?: Byron L. Dorgan has not been actively trading shares of Codexis in the last ninety days. Most recently, Byron L. Dorgan sold 20,000 shares of the business's stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $2.11, for a transaction totalling $42,200.00. Following the completion of the sale, the director now directly owns 193,461 shares of the company's stock, valued at $408,202.71. Learn More on Byron L. Dorgan's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, Codexis insiders bought shares 3 times. They purchased a total of 32,484 shares worth more than $55,402.80. In the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,000 shares worth more than $42,200.00. The most recent insider tranaction occured on November, 15th when Director Byron L Dorgan sold 20,000 shares worth more than $42,200.00. Insiders at Codexis own 6.3% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 11/15/2023.

Byron L. Dorgan Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2023	Sell	20,000	$2.11	$42,200.00	193,461
10/18/2021	Sell	20,000	$27.94	$558,800.00
2/21/2020	Sell	16,702	$14.02	$234,162.04	153,838
7/16/2018	Sell	10,000	$15.49	$154,900.00	190,593

Byron L. Dorgan Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.83

$2.71

$2.87

50 Day Range

MA: $3.32

$2.69

$4.65

2 Week Range

Now: $2.83

$1.45

$4.91

Volume

465,339 shs

Average Volume

572,124 shs

Market Capitalization

$198.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad